A bill to provide for a cost and affordability review of certain prescription drug products; to create the prescription drug pricing board and prescription drug affordability stakeholder council and to prescribe their powers and duties; to provide for the powers and duties of certain state governmental officers and entities; to establish upper payment limits for certain prescription drug products and provide remedies; and to provide for the promulgation of rules.
Senate Bill 483 (S-1) would create the Prescription Drug Affordability Board (Board) and the Prescription Drug Affordability Stakeholder Council (Council). The Board would have to select prescription drug products based on specified criteria and costs and determine whether to conduct cost and affordability reviews for those products based on their average patient cost share. Upon review, the Board could decide to establish an upper payment limit on a prescription drug product, which is a cap on the amount that a prescription drug purchaser or payer could pay for the product. The bill also would allow the Attorney General to pursue civil actions for a violation of an upper payment limit and subject the bills' provisions to appropriation. The other two bills would require insurers in the State and the Healthy Michigan Plan to comply with upper payment limits on prescription drug products. Senate Bill 484 would amend the Insurance Code to require an insurer that offered health insurance policies in the State to comply with upper payment limits established under Senate Bill 483 (S-1). Senate Bill 485 would amend the Social Welfare Act to require the Medical Assistance Program (Medicaid) to comply with upper payment limits established under Senate Bill 483 (S-1).
Co-sponsored by Sens.
Referred to the Committee on Finance, Insurance, and Consumer Protection
Reported with substitute S-1
Referred to the Committee of the Whole
Reported with substitute S-1
Substitute S-1 concurred in by voice vote
1. Amend page 4, line 20, after “activities.” by inserting “The governor shall not appoint an individual to the board if the individual is a lobbyist who is registered in this state. An individual who is appointed to the board shall not register as a lobbyist in this state for a period of 5 years after the individual’s term on the board expires.”.
The amendment passed 37 to 0 (details)
1. Amend page 4, line 20, after “activities.” by inserting “The governor shall not appoint an individual to the board if the individual has made a personal political contribution to the governor.”.
The amendment failed 17 to 20 (details)
1. Amend page 4, line 13, after “medicine.” by inserting “At least 1 member of the board must be an individual who advocates for patients.”.
The amendment failed 17 to 20 (details)
1. Amend page 15, following line 18, by inserting:
“Sec. 24. This act does not apply beginning 3 years after the effective date of this act.”.
The amendment failed 17 to 20 (details)
1. Amend page 12, following line 7, by inserting:
“(j) The cost of manufacturing the prescription drug product.” and relettering the remaining subdivision.
The amendment failed 17 to 20 (details)
1. Amend page 2, line 11, after “the” by inserting “medical care component of the”.
2. Amend page 2, line 12, after “Index” by striking out “for all urban consumers as defined and” and inserting “as”.
The amendment failed by voice vote
Passed in the Senate 20 to 17 (details)
Referred to the Committee on Insurance and Financial Services
